| Year |
Citation |
Score |
| 2022 |
Yamamoto Y, Ishii M, Yoshimura A, Hayashi T, Kawamura N, Nagahara A, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K. Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 36168966 DOI: 10.1111/iju.15052 |
0.337 |
|
| 2021 |
Sugimoto K, Tabuchi T, Okawa S, Morishima T, Koyama S, Nakayama M, Nishimura K, Miyashiro I. Hospital volume and postoperative survival for three urological cancers: Prostate, kidney, and bladder. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 34050559 DOI: 10.1111/iju.14573 |
0.304 |
|
| 2021 |
Iguchi T, Kimura G, Fukasawa S, Suzuki H, Uemura H, Nishimura K, Matsumoto H, Yokomizo A, Armstrong AJ, Rosbrook B, Sugg J, Baron B, Chen L, Kunieda F, Stenzl A. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 33955599 DOI: 10.1111/iju.14568 |
0.3 |
|
| 2020 |
Uemura H, Arai G, Uemura H, Suzuki H, Iijima K, Nishimura K, Fujii K, Hatayama T, Aoyama J, Deprince K, Lopez-Gitlitz A, McCarthy S, Larsen JS, Li J, Chi KN. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 33295007 DOI: 10.1111/iju.14447 |
0.304 |
|
| 2020 |
Nakai Y, Kanaki T, Yamamoto A, Tanaka R, Yamamoto Y, Nagahara A, Nakayama M, Kakimoto KI, Ishibashi M, Nishimura K. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents. Journal of Bone and Mineral Metabolism. PMID 32886176 DOI: 10.1007/S00774-020-01151-9 |
0.366 |
|
| 2020 |
Yamamoto Y, Okuda Y, Kanaki T, Tanaka R, Nagahara A, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. International Journal of Clinical Oncology. PMID 32875513 DOI: 10.1007/S10147-020-01776-W |
0.391 |
|
| 2020 |
Tomita Y, Tatsugami K, Nakaigawa N, Osawa T, Oya M, Kanayama H, Nakayama Kondoh C, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Tanaka S, Kimura A, et al. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 32789967 DOI: 10.1111/Iju.14329 |
0.345 |
|
| 2020 |
Asakura T, Nakai Y, Oka T, Okuda Y, Hatano K, Nakayama M, Kakimoto K, Nishimura K. [A Case of Myocardial Metastasis of Renal Cell Cancer Treated with Nivolumab]. Hinyokika Kiyo. Acta Urologica Japonica. 66: 225-228. PMID 32723977 DOI: 10.14989/Actauroljap_66_7_225 |
0.385 |
|
| 2020 |
Ito K, Kobayashi M, Komiyama M, Naito S, Nishimura K, Yonese J, Hashine K, Saito S, Arai G, Shinohara M, Masumori N, Shimizu N, Satoh T, Yamauchi A, Tochigi T, et al. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial. Cancer. PMID 32573779 DOI: 10.1002/Cncr.33034 |
0.394 |
|
| 2020 |
Yumiba S, Nakayama M, Kuribayashi S, Tsuji H, Hatano K, Nakai Y, Kakimoto KI, Nishimura K. [A Case of Primary Central Nervous System Lymphoma that Developed during the Treatment of Castration-Resistant Prostate Cancer]. Hinyokika Kiyo. Acta Urologica Japonica. 66: 49-52. PMID 32160733 DOI: 10.14989/Actauroljap_66_2_49 |
0.443 |
|
| 2020 |
Nagahara A, Kanaki T, Yamamoto A, Yamamoto Y, Nakai Y, Nakayama M, Kakimoto K, Konishi K, Teshima T, Nishimura K. The efficacy of metastasis-directed radiation therapy (MDRT) for oligometastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 38: 240-240. DOI: 10.1200/Jco.2020.38.6_Suppl.240 |
0.382 |
|
| 2020 |
Oya M, Tamada S, Tatsugami K, Nakaigawa N, Osawa T, Kanayama H, Kondoh C, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kimura A, Kuroda S, Motzer RJ, et al. A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma. Journal of Clinical Oncology. 38: 5089-5089. DOI: 10.1200/Jco.2020.38.15_Suppl.5089 |
0.333 |
|
| 2019 |
Hatano K, Tanaka J, Nakai Y, Nakayama M, Kakimoto KI, Nakanishi K, Nishimura K. Utility of index lesion volume assessed by multiparametric MRI combined with Gleason grade for assessment of lymph node involvement in patients with high-risk prostate cancer. Japanese Journal of Clinical Oncology. PMID 31829421 DOI: 10.1093/Jjco/Hyz170 |
0.355 |
|
| 2019 |
Nishiyama H, Yamamoto Y, Sassa N, Nishimura K, Fujimoto K, Fukasawa S, Yokoyama M, Enokida H, Takahashi K, Tanaka Y, Imai K, Shimamoto T, Perini R, Frenkl T, Bajorin D, et al. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. International Journal of Clinical Oncology. PMID 31729625 DOI: 10.1007/S10147-019-01545-4 |
0.38 |
|
| 2019 |
Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 31055879 DOI: 10.1111/Iju.14009 |
0.395 |
|
| 2019 |
Nakayama M, Ito Y, Hatano K, Nakai Y, Kakimoto KI, Miyashiro I, Nishimura K. Impact of sex difference on survival of bladder cancer: A population-based registry data in Japan. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 30916420 DOI: 10.1111/Iju.13955 |
0.329 |
|
| 2018 |
Takada M, Yasui T, Oka T, Shioyama W, Kuroda T, Nakai Y, Nishimura K, Mukai M, Fujita M. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma. International Heart Journal. PMID 30158382 DOI: 10.1536/Ihj.17-461 |
0.337 |
|
| 2018 |
Onozawa M, Akaza H, Hinotsu S, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Tsukamoto T. Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching. Cancer Medicine. PMID 30151999 DOI: 10.1002/Cam4.1735 |
0.412 |
|
| 2017 |
Kanda S, Okubo K, Hida T, Kono J, Takahashi T, Mitsumori K, Shimada T, Nishimura K. [A Case of Secondary Extramammary Paget's Disease Aroundthe Cutaneous Stoma after Radical Cystectomy]. Hinyokika Kiyo. Acta Urologica Japonica. 63: 381-386. PMID 28992669 DOI: 10.14989/Actauroljap_63_9_381 |
0.312 |
|
| 2017 |
Takizawa A, Kawai K, Kawahara T, Kojima T, Maruyama S, Shinohara N, Akamatsu S, Kamba T, Nakamura T, Ukimura O, Jikuya R, Kishida T, Kakimoto K, Nishimura K, Harabayashi T, et al. The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor. Journal of Cancer Research and Clinical Oncology. PMID 28905168 DOI: 10.1007/S00432-017-2520-5 |
0.301 |
|
| 2017 |
Yoshioka Y, Kotsuma T, Komiya A, Kariya S, Konishi K, Nonomura N, Ogawa K, Tanaka E, Nishimura K, Fujiuchi Y, Kitamura H, Yamagami T, Yamasaki I, Nishimura K, Teshima T, et al. Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 97: 952-961. PMID 28333018 DOI: 10.1016/J.Ijrobp.2016.12.013 |
0.381 |
|
| 2017 |
Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. Japanese Journal of Clinical Oncology. PMID 28042138 DOI: 10.1093/Jjco/Hyw193 |
0.376 |
|
| 2017 |
Hatano K, Okusa T, Ishizuya Y, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K. Postoperative early ultrasensitive prostate-specific antigen identifies patients at risk for biochemical recurrence in margin positive prostate cancers: a single-center study. Japanese Journal of Clinical Oncology. 47: 74-79. PMID 27733509 DOI: 10.1093/Jjco/Hyw150 |
0.404 |
|
| 2017 |
Inokuchi J, Kuroiwa K, Kakehi Y, Sugimoto M, Tanikawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yamaguchi A, Matsuyama H, Ichikawa T, Asano T, ... ... Nishimura K, et al. Mp71-18 Distribution Of Lymph Node Metastasis In Upper Urinary Tract Urothelial Cancer, Sub-Analysis Of Jcog1110A Study The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2274 |
0.305 |
|
| 2016 |
Ishizuya Y, Okusa T, Hatano K, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K. [A Case of Renal Cell Carcinoma with Malignant Pleural Effusion Showing Marked Response to Axitinib]. Hinyokika Kiyo. Acta Urologica Japonica. 62: 525-528. PMID 27919126 DOI: 10.14989/Actauroljap_62_10_525 |
0.332 |
|
| 2016 |
Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, Chung BH, Chen CH, Fai NC, ... ... Nishimura K, et al. Asia prostate cancer study (A-CaP Study) launch symposium. Prostate International. 4: 88-96. PMID 27689065 DOI: 10.1016/J.Prnil.2016.03.001 |
0.397 |
|
| 2016 |
Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Prognosis of metastatic renal cell carcinoma with first-line Interferon-α therapy in the era of molecular-targeted therapy. Cancer Science. PMID 27089226 DOI: 10.1111/Cas.12951 |
0.353 |
|
| 2016 |
Kimura G, Yonese J, Fukagai T, Kamba T, Nishimura K, Nozawa M, Mansbach H, Theeuwes A, Beer TM, Tombal B, Ueda T. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 27018069 DOI: 10.1111/Iju.13072 |
0.419 |
|
| 2016 |
Low SK, Fukunaga K, Takahashi A, Matsuda K, Hongo F, Nakanishi H, Kitamura H, Inoue T, Kato Y, Tomita Y, Fukasawa S, Tanaka T, Nishimura K, Uemura H, Hara I, et al. Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction. Plos One. 11: e0148177. PMID 26914831 DOI: 10.1371/Journal.Pone.0148177 |
0.318 |
|
| 2016 |
Matsuzaki K, Yoshida T, Kobayashi Y, Takeda K, Arai Y, Nakayama M, Kakimoto K, Tomita Y, Nishimura K. Squamous Cell Carcinoma Arising from Aparaurethral Region Case Reports in Clinical Medicine. 5: 154-157. DOI: 10.4236/Crcm.2016.54029 |
0.357 |
|
| 2015 |
Yoshida T, Okuyama H, Nakayama M, Endo H, Tomita Y, Nonomura N, Nishimura K, Inoue M. Dynamic Change in p63 Protein Expression during Implantation of Urothelial Cancer Clusters. Neoplasia (New York, N.Y.). 17: 574-85. PMID 26297435 DOI: 10.1016/J.Neo.2015.07.004 |
0.344 |
|
| 2015 |
Urushima H, Inomata-Kurashiki Y, Nishimura K, Sumi R, Shimomura I, Nonomura N, Ito T, Maeda K. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients. The Aging Male : the Official Journal of the International Society For the Study of the Aging Male. 18: 72-6. PMID 25746209 DOI: 10.3109/13685538.2015.1017809 |
0.34 |
|
| 2015 |
Yamaguchi Y, Hayashi Y, Ishizuya Y, Takeda K, Nakai Y, Arai Y, Nakayama M, Kakimoto K, Nishimura K. A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score. Japanese Journal of Clinical Oncology. 45: 197-201. PMID 25381383 DOI: 10.1093/Jjco/Hyu186 |
0.422 |
|
| 2015 |
Yoshida T, Okuyama H, Nakayama M, Endo H, Nonomura N, Nishimura K, Inoue M. High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids. Cancer Science. 106: 69-77. PMID 25363302 DOI: 10.1111/Cas.12567 |
0.388 |
|
| 2015 |
Kobayashi Y, Nakayama M, Matsuzaki K, Takeda K, Yoshida T, Arai Y, Kakimoto K, Yuki M, Tomita Y, Ono Y, Nishimura K. Liposarcoma arising from the right renal sinus with inferior vena caval involvement Journal of Solid Tumors. 5: 69. DOI: 10.5430/Jst.V5N2P69 |
0.31 |
|
| 2015 |
Hayashi Y, Ishizuya Y, Takeda K, Yamaguchi Y, Nakayama M, Arai Y, Kakimoto K, Tomita Y, Nishimura K. Desmoid Tumor Mimicking Port Site Recurrence after Laparoscopic Retroperitoneal Lymph Node Dissection for Metastatic Testicular Tumor: A Case Report Case Reports in Clinical Medicine. 4: 179-183. DOI: 10.4236/Crcm.2015.45036 |
0.31 |
|
| 2015 |
Kimura G, Yonese J, Fukagai T, Kamba T, Nishimura K, Nozawa M, Mansbach HH, Phung D, Beer TM, Tombal BF, Ueda T. Subgroup analyses of Japanese patients from the PREVAIL trial of enzalutamide (ENZA) in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 265-265. DOI: 10.1200/Jco.2015.33.7_Suppl.265 |
0.401 |
|
| 2015 |
Kawashima A, Uemura M, Nagahara A, Yamamoto Y, Takada S, Inagaki Y, Kinouchi T, Miyake O, Nakazawa S, Nishimura K, Arai H, Honda M, Okada K, Tsujihata M, Tsutahara K, et al. 248P GnRH antagonist plus bicalutamide might be an effective therapy as initial combined androgen blockade for patients with high grade prostate cancer Annals of Oncology. 26: ix71. DOI: 10.1093/ANNONC/MDV524.13 |
0.316 |
|
| 2014 |
Yamamoto Y, Nakayama M, Ueda N, Takeda K, Nakata W, Kakimoto K, Nishimura K. [Risk factors of recurrence after radical prostatectomy for locally advanced prostate cancer]. Nihon HinyåKika Gakkai Zasshi. the Japanese Journal of Urology. 105: 91-6. PMID 25158550 DOI: 10.5980/Jpnjurol.105.91 |
0.426 |
|
| 2014 |
Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Akaza H. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Japanese Journal of Clinical Oncology. 44: 969-81. PMID 25098707 DOI: 10.1093/Jjco/Hyu104 |
0.43 |
|
| 2014 |
Inamoto T, Azuma H, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, Kazuhiro S, Naito S, Namiki M, Nishimura K, Hirao Y, Usami M, Murai M, Akaza H, et al. Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort. Journal of Cancer Research and Clinical Oncology. 140: 1197-204. PMID 24676427 DOI: 10.1007/S00432-014-1638-Y |
0.404 |
|
| 2014 |
Inamoto T, Azuma H, Nonomura N, Nakatani T, Matsuda T, Nozawa M, Ueda T, Kinoshita H, Nishimura K, Kanayama HO, Miki T, Tomita Y, Yoshioka T, Tsujihata M, Uemura H. Favorable outcome in elderly Asian patients with metastatic renal cell carcinoma treated with everolimus: the Osaka Urologic Oncology Group. Asian Pacific Journal of Cancer Prevention : Apjcp. 15: 1811-5. PMID 24641414 DOI: 10.7314/Apjcp.2014.15.4.1811 |
0.361 |
|
| 2014 |
Nakai Y, Nishimura K, Nakayama M, Uemura M, Takayama H, Nonomura N, Tsujimura A. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: Its efficacy and safety profile compared with tri-weekly standard-dose treatment International Journal of Clinical Oncology. 19: 165-172. PMID 23456140 DOI: 10.1007/S10147-013-0536-7 |
0.374 |
|
| 2014 |
Ozono S, Oyama M, Nozawa M, Fujimoto K, Kishida K, Tokuda N, Kimura G, Nishimura K, Matsubara A, Matsuyama H, Sugiyama T, Kamba T, Kume H, Masumori N, Oya M, et al. Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy. Journal of Clinical Oncology. 32: 455-455. DOI: 10.1200/Jco.2014.32.4_Suppl.455 |
0.341 |
|
| 2014 |
Kakimoto K, Hayashi Y, Ishizuya Y, Takeda K, Yamaguchi Y, Arai Y, Nakayama M, Nishimura K. Clinical outcome of patients with metastatic seminomatous germ cell tumor: Results of a single high-volume cancer center in Japan. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E15539 |
0.404 |
|
| 2014 |
Yoshida T, Okuyama H, Nakayama M, Nishimura K, Nonomura N, Inoue M. Abstract 1341: Rapid decrease of ATP followed by necrosis-like cell death in bladder cancer cells after exposure to high-dose chemotherapeutics used in intravesical therapy Cancer Research. 74: 1341-1341. DOI: 10.1158/1538-7445.Am2014-1341 |
0.356 |
|
| 2014 |
Yoshida T, Okuyama H, Nakayama M, Nishimura K, Inoue M, Nonomura N. Mp21-07 High-Dose Chemotherapeutics Used In Intravesical Therapy Induce Mitochondrial Dysfunction Followed By Necrosis-Like Cell Death In Bladder Cancer Cells The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.835 |
0.346 |
|
| 2013 |
Nozawa M, Nonomura N, Ueda T, Nishimura K, Kanayama HO, Miki T, Nakatani T, Tomita Y, Azuma H, Yoshioka T, Tsujihata M, Uemura H. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. Japanese Journal of Clinical Oncology. 43: 1132-8. PMID 23999768 DOI: 10.1093/Jjco/Hyt121 |
0.348 |
|
| 2013 |
Okuyama H, Yoshida T, Endo H, Nakayama M, Nonomura N, Nishimura K, Inoue M. Involvement of heregulin/HER3 in the primary culture of human urothelial cancer. The Journal of Urology. 190: 302-10. PMID 23313199 DOI: 10.1016/J.Juro.2012.12.106 |
0.332 |
|
| 2013 |
Yoshioka Y, Suzuki O, Nishimura K, Inoue H, Hara T, Yoshida K, Imai A, Tsujimura A, Nonomura N, Ogawa K. Analysis of late toxicity associated with external beam radiation therapy for prostate cancer with uniform setting of classical 4-field 70 Gy in 35 fractions: a survey study by the Osaka Urological Tumor Radiotherapy Study Group. Journal of Radiation Research. 54: 113-25. PMID 22988284 DOI: 10.1093/Jrr/Rrs083 |
0.315 |
|
| 2013 |
Yamada T, Nakayama M, Shimizu T, Nonen S, Nakai Y, Nishimura K, Fujio Y, Okuyama A, Azuma J, Nonomura N. Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy. International Journal of Clinical Oncology. 18: 711-7. PMID 22714708 DOI: 10.1007/S10147-012-0430-8 |
0.408 |
|
| 2013 |
Hatano K, Nishimura K, Nakai Y, Yoshida T, Sato M, Kawashima A, Mukai M, Nagahara A, Uemura M, Oka D, Nakayama M, Takayama H, Shimizu K, Meguro N, Tanigawa T, et al. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology. 18: 704-10. PMID 22688162 DOI: 10.1007/S10147-012-0429-1 |
0.426 |
|
| 2013 |
Nishimura K, Nonomura N, Hashine K, Kanayama HO, Ozono S, Miura T, Miki T, Kakehi Y, Arai Y, Ogawa O, Fujita R, Nonomura K, Mizokami A, Hoshi S, Akaza H. Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan. International Journal of Clinical Oncology. 18: 306-13. PMID 22350099 DOI: 10.1007/S10147-012-0380-1 |
0.406 |
|
| 2013 |
Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Importance of performance status, corrected calcium, and microvascular invasion in predicting overall survival in patients with metastatic renal cell carcinoma at the era of molecular targeted therapy. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E15588 |
0.361 |
|
| 2013 |
Inoue M, Endo H, Ohue M, Nishimura K, Imamura F, Okami J, Okuyama H. Abstract 3832: Cancer tissue-derived spheroid, CTOS, for evaluation of drug response from individual patient tumor samples. Cancer Research. 73: 3832-3832. DOI: 10.1158/1538-7445.Am2013-3832 |
0.386 |
|
| 2012 |
Kakimoto KI, Takeda K, Nakata W, Nakayama M, Arai Y, Nishimura K. Clinical outcome of extragonadal germ cell tumors: Retrospective analysis at a single institution in Japan. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 345. PMID 27968006 DOI: 10.1200/Jco.2012.30.5_Suppl.345 |
0.356 |
|
| 2012 |
Hinotsu S, Akaza H, Ogawa O, Oya M, Kitamura T, Suzuki K, Tsukamoto T, Naito S, Namiki M, Nishimura K, Hirao Y. Hormonal therapy for localized prostate cancer in Japan: The outcome of J-CaP database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 54. PMID 27967865 DOI: 10.1200/Jco.2012.30.5_Suppl.54 |
0.434 |
|
| 2012 |
Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, Uemura M, Nakai Y, Nishimura K, Nonomura N. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. International Journal of Urology : Official Journal of the Japanese Urological Association. 19: 1050-7. PMID 22860625 DOI: 10.1111/j.1442-2042.2012.03115.x |
0.362 |
|
| 2012 |
Kawashima A, Takayama H, Kawamura N, Doi N, Sato M, Hatano K, Nagahara A, Uemura M, Nakai Y, Nishimura K, Miyoshi S, Kawano K, Nishimura K, Nonomura N, Tsujimura A. Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. Oncology Letters. 4: 15-21. PMID 22807952 DOI: 10.3892/Ol.2012.689 |
0.339 |
|
| 2012 |
Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, Yasunaga Y, Mukai M, Uemura M, Nakai Y, Nishimura K, Nonomura N. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. Medical Oncology (Northwood, London, England). 29: 3298-305. PMID 22544539 DOI: 10.1007/S12032-012-0236-6 |
0.376 |
|
| 2012 |
Yoshida T, Nakayama M, Takeda K, Arai Y, Kakimoto K, Nishimura K. External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients. Urologia Internationalis. 89: 45-51. PMID 22441013 DOI: 10.1159/000336924 |
0.409 |
|
| 2012 |
Kawashima A, Nakai Y, Nakayama M, Ujike T, Tanigawa G, Ono Y, Kamoto A, Takada T, Yamaguchi Y, Takayama H, Nishimura K, Nonomura N, Tsujimura A. The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study World Journal of Urology. 30: 701-706. PMID 21984472 DOI: 10.1007/S00345-011-0775-Z |
0.322 |
|
| 2012 |
Yoshida T, Matsuzaki K, Kobayashi Y, Takeda K, Nakayama M, Arai Y, Kakimoto K, Nishimura K. Usefulness of postoperative nadir prostate-specific antigen value by ultrasensitive assay as a predictor of prostate-specific antigen relapse for pathological T3 or positive surgical margins after radical prostatectomy for prostate cancer. International Urology and Nephrology. 44: 479-85. PMID 21822599 DOI: 10.1007/S11255-011-0044-5 |
0.391 |
|
| 2012 |
Takayama H, Kawashima A, Arai Y, Nin M, Tanigawa G, Yasunaga Y, Nomura H, Mukai M, Yoshioka T, Uemura M, Nakai Y, Nishimura K, Tsujimura A, Nonomura N, Study ORCCC. The effect of continuing therapy for more than one course and CRP level on PFS and OS in the general practice of sunitinib therapy in Japanese patients with metastatic renal cancer. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15069 |
0.388 |
|
| 2012 |
Uemura M, Tsujimura A, Kawashima A, Arai Y, Tanigawa G, Nin M, Yasunaga Y, Yoshioka T, Nomura H, Mukai M, Fukuda S, Oka D, Nishimura K, Yoshida T, Satou M, ... ... Nishimura K, et al. Gender as a factor associated with poor compliance in the treatment of metastatic renal cell carcinoma with VEGF-targeted therapy in Japanese patients. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15065 |
0.386 |
|
| 2012 |
Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S. Use of STAT3 polymorphisms to predict overall survival in patients treated with interferon-alpha for metastatic renal cell carcinoma. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E15048 |
0.309 |
|
| 2011 |
Nishimura K, Yamamoto Y, Nakayama M, Kakimoto K. [Controversy over treatment options in clinical T3 prostate cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 38: 2548-52. PMID 22189219 |
0.309 |
|
| 2011 |
Yoshida T, Nakayama M, Matsuzaki K, Kobayashi Y, Takeda K, Arai Y, Kakimoto K, Nishimura K. Validation of the Prostate Cancer Risk Index (PRIX): a simple scoring system to predict risk of biochemical relapse after radical prostatectomy for prostate cancer. Japanese Journal of Clinical Oncology. 41: 1271-6. PMID 21971422 DOI: 10.1093/Jjco/Hyr139 |
0.402 |
|
| 2011 |
Tanigawa G, Kawashima A, Yamaguchi S, Nishimura K, Miyoshi S, Kajikawa J, Meguro N, Yosioka T, Oka T, Hara T, Takayama H, Nonomura N. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Japanese Journal of Clinical Oncology. 41: 1265-70. PMID 21965163 DOI: 10.1093/Jjco/Hyr137 |
0.349 |
|
| 2011 |
Yoshida T, Nakayama M, Suzuki O, Matsuzaki K, Kobayashi Y, Takeda K, Arai Y, Kakimoto K, Nishiyama K, Nishimura K. Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience. Japanese Journal of Clinical Oncology. 41: 1031-6. PMID 21693484 DOI: 10.1093/Jjco/Hyr078 |
0.404 |
|
| 2011 |
Kawashima A, Nakayama M, Oka D, Sato M, Hatano K, Mukai M, Nagahara A, Nakai Y, Takayama H, Inoue M, Shiono H, Nishimura K, Okumura M, Nonomura N. Pulmonary metastasectomy in patients with renal cell carcinoma: A single-institution experience International Journal of Clinical Oncology. 16: 660-665. PMID 21556800 DOI: 10.1007/S10147-011-0244-0 |
0.329 |
|
| 2011 |
Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, Imazu T, Kinoshita T, Yasunaga Y, Inoue H, Nishimura K, Takada S, Nishimura K, Tsujimura A, Nonomura N, et al. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. European Journal of Cancer (Oxford, England : 1990). 47: 1521-6. PMID 21550799 DOI: 10.1016/J.Ejca.2011.04.001 |
0.367 |
|
| 2011 |
Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, Mukai M, Nagahara A, Nakai Y, Oka D, Takayama H, Yoshioka T, Hoshida Y, Itatani H, Nishimura K, Nonomura N. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2561-9. PMID 21177407 DOI: 10.1158/1078-0432.Ccr-10-1963 |
0.362 |
|
| 2011 |
Hatano K, Nonomura N, Nishimura K, Kawashima A, Mukai M, Nagahara A, Nakai Y, Nakayama M, Takayama H, Tsujimura A, Okuyama A. Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer. Japanese Journal of Clinical Oncology. 41: 253-9. PMID 21071389 DOI: 10.1093/Jjco/Hyq178 |
0.427 |
|
| 2011 |
Kawashima A, Nakayama M, Kakuta Y, Abe T, Sato M, Hatano K, Mukai M, Nagahara A, Oka D, Nakai Y, Takayama H, Yoshioka T, Hoshida Y, Itatani H, Nishimura K, et al. Abstract 2475: Excision repair cross complementing group 1 (ERCC1) predicts the efficacy of chemoradiotherapy for invasive bladder cancer Cancer Research. 71: 2475-2475. DOI: 10.1158/1538-7445.Am2011-2475 |
0.375 |
|
| 2011 |
Nishimura K, Okuyama H, Takeda K, Yoshida T, Arai Y, Nakayama M, Kakimoto K, Inoue M. 875 Primary Culture Of Human Bladder Tumor By Cancer Tissue-Originated Spheroid The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.699 |
0.323 |
|
| 2011 |
Nakayama M, Yamada T, Shimizu T, Nonen S, Nishimura K, Nishimura K, Hara T, Tanigawa G, Yoshioka T, Hatano K, Nakai Y, Takayama H, Fujio Y, Azuma J, Okuyama A, et al. 2289 Genetic Polymorphisms Of Cyp17A1 May Predict Early Progression After Primary Androgen Deprivation Therapy In Japanese Men With Prostate Cancer The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2534 |
0.379 |
|
| 2011 |
Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, Imazu T, Kinoshita T, Yasunaga Y, Inoue H, Takada S, Nishimura K, Murosaki N, Saiki S, Fujimoto N, ... ... Nishimura K, et al. 1772 Less Than 50% Of One Month Relative Dose Intensity Is The Poor Prognostic Factor Of Sorafenib Therapy For Cytokine Refractory Renal Cell Carcinoma The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2100 |
0.359 |
|
| 2011 |
Kawashima A, Nakai Y, Nakayama M, Ujike T, Tanigawa G, Takeda K, Ono Y, Yoshioka T, Takada T, Yamaguchi Y, Sato M, Hatano K, Mukai M, Nagahara A, Oka D, ... ... Nishimura K, et al. 672 Adjuvant Platinum-Based Chemotherapy Improved The Prognosis Of Patients With Pt3N0/Xm0 Upper Urinary Tract Carcinoma The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1602 |
0.339 |
|
| 2011 |
Kawashima A, Nakayama M, Kakuta Y, Abe T, Sato M, Hatano K, Mukai M, Nagahara A, Oka D, Nakai Y, Takayama H, Yoshioka T, Hoshida Y, Itatani H, Nishimura K, et al. 510 Excision Repair Cross-Complementing Group 1 (Ercc1) May Predict The Efficacy Of Chemoradiotherapy For Bladder Cancer The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1206 |
0.301 |
|
| 2010 |
Uemura M, Honma S, Chung S, Takata R, Furihata M, Nishimura K, Nonomura N, Nasu Y, Miki T, Shuin T, Fujioka T, Okuyama A, Nakamura Y, Nakagawa H. 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. Cancer Science. 101: 1897-904. PMID 20560974 DOI: 10.1111/J.1349-7006.2010.01620.X |
0.369 |
|
| 2010 |
Nonomura N, Takayama H, Kawashima A, Mukai M, Nagahara A, Nakai Y, Nakayama M, Tsujimura A, Nishimura K, Aozasa K, Okuyama A. Decreased infiltration of macrophage scavenger receptor-positive cells in initial negative biopsy specimens is correlated with positive repeat biopsies of the prostate. Cancer Science. 101: 1570-3. PMID 20384632 DOI: 10.1111/J.1349-7006.2010.01563.X |
0.428 |
|
| 2010 |
Nakai Y, Nonomura N, Kawashima A, Mukai M, Nagahara A, Nakayama M, Takayama H, Nishimura K, Okuyama A. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer. Japanese Journal of Clinical Oncology. 40: 252-7. PMID 19995789 DOI: 10.1093/Jjco/Hyp159 |
0.354 |
|
| 2010 |
Takayama H, Hatano K, Kawashima A, Mukai M, Nagahara A, Nakai Y, Nakayama M, Nishimura K, Okuyama A, Nonomura N. Abstract 4634: Decreased infiltration of macrophage scavenger receptor in non-malignant biopsy specimens is associated with detection of prostate cancer Cancer Research. 70: 4634-4634. DOI: 10.1158/1538-7445.Am10-4634 |
0.442 |
|
| 2010 |
Nagahara A, Nakayama M, Oka D, Hatano K, Kawashima A, Mukai M, Uemura M, Nakai Y, Takayama H, NIshimura K, Jo Y, Nagai A, Okuyama A, Nonomura N. Abstract 3293: Possible role of SERPINE2 in lymph node metastasis of testicular cancer Cancer Research. 70: 3293-3293. DOI: 10.1158/1538-7445.Am10-3293 |
0.313 |
|
| 2009 |
Fujita K, Nakayama M, Nakai Y, Takayama H, Nishimura K, Ujike T, Nishimura K, Aozasa K, Okuyama A, Nonomura N. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy. Cancer Science. 100: 1047-50. PMID 19385972 DOI: 10.1111/J.1349-7006.2009.01146.X |
0.356 |
|
| 2009 |
Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. The Journal of Urology. 181: 1894-900. PMID 19237175 DOI: 10.1016/J.Juro.2008.11.090 |
0.362 |
|
| 2009 |
Takayama H, Nonomura N, Nishimura K, Oka D, Shiba M, Nakai Y, Nakayama M, Tsujimura A, Aozasa K, Okuyama A. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer. Bju International. 103: 470-4. PMID 18778349 DOI: 10.1111/J.1464-410X.2008.08013.X |
0.42 |
|
| 2009 |
Nakayama M, Fujita K, Kawashima A, Mukai M, Nagahara A, Nakai Y, Takayama H, Nishimura K, Aozasa K, Okuyama A, Nonomura N. Vegfr1 Expression In Pelvic Lymph Nodes Predicts The Risk Of Biochemical Recurrence After Radical Prostatectomy The Journal of Urology. 181: 99-99. DOI: 10.1016/S0022-5347(09)60283-4 |
0.45 |
|
| 2008 |
Tsujihata M, Nonomura N, Momohara C, Nishimura K, Tsujimura A, Okuyama A. Clinical experience with laparoscopic radical nephrectomy for renal cell carcinoma. Urologia Internationalis. 81: 301-5. PMID 18931547 DOI: 10.1159/000151408 |
0.317 |
|
| 2008 |
Takayama H, Nonomura N, Nakai Y, Oka D, Shiba M, Nakayama M, Nishimura K, Okuyama A. WS1-3-4 Decreased Infiltration of Macrophage Scavenger Receptor Is Associated with Poor Prognosis of Prostate Cancer(Prostate Cancer) The Japanese Journal of Urology. 99: 148. DOI: 10.5980/Jpnjurol.99.148_2 |
0.415 |
|
| 2008 |
Takayama H, Nonomura N, Mukai M, Nagahara A, Shiba M, Oka D, Nakai Y, Nakayama M, Nishimura K, Okuyama A. Decreased Infiltration Of Not Tumor-Associated Macrophages But Macrophage Scavenger Receptor In Non-Malignant Biopsy Is Associated With Detection Of Prostate Cancer The Journal of Urology. 179: 640-640. DOI: 10.1016/S0022-5347(08)61873-X |
0.397 |
|
| 2008 |
Nakayama M, Tsuzuki T, Mukai M, Nagahara A, Oka D, Nakai Y, Shiba M, Takayama H, Inoue H, Nishimura K, Nelson WG, Marzo AMD, Nonomura N, Okuyama A. Gstp1 Hypermethylation In Prostate Biopsy Washing Is A New Biomarker For Repeat Prostate Biopsy The Journal of Urology. 179: 604-604. DOI: 10.1016/S0022-5347(08)61770-X |
0.36 |
|
| 2008 |
Takayama H, Nonomura N, Mukai M, Nagahara A, Shiba M, Oka D, Nakai Y, Nakayama M, Nishimura K, Okuyama A. Increased Infiltration Of Tumor-Associated Macrophages Is Associated With Poor Prognosis Of Carcinoma In Situ Of Bladder Treated With Intravesical Bacillus Calmette- Guérin The Journal of Urology. 179: 326-326. DOI: 10.1016/S0022-5347(08)60954-4 |
0.353 |
|
| 2007 |
Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, Tsujimura A, Nakayama M, Aozasa K, Okuyama A. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. British Journal of Cancer. 97: 952-6. PMID 17848955 DOI: 10.1038/sj.bjc.6603962 |
0.315 |
|
| 2007 |
Nonomura N, Oka D, Nishimura K, Nakayama M, Inoue H, Mizutani Y, Miki T, Okuyama A. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors. International Journal of Urology : Official Journal of the Japanese Urological Association. 14: 527-31. PMID 17593098 DOI: 10.1111/J.1442-2042.2006.01702.X |
0.404 |
|
| 2007 |
Oka D, Nishimura K, Shiba M, Nakai Y, Arai Y, Nakayama M, Takayama H, Inoue H, Okuyama A, Nonomura N. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. International Journal of Cancer. 120: 2576-81. PMID 17290398 DOI: 10.1002/Ijc.22570 |
0.314 |
|
| 2006 |
Saito J, Takayama H, Kakuta Y, Miyagawa Y, Tsujihata M, Nishimura K, Nonomura N, Okuyama A. [The growing teratoma syndrome report of a case]. Nihon HinyōKika Gakkai Zasshi. the Japanese Journal of Urology. 97: 796-800. PMID 17025213 DOI: 10.5980/Jpnjurol1989.97.796 |
0.31 |
|
| 2006 |
Nonomura N, Nakai Y, Nakayama M, Inoue H, Nishimura K, Hatanaka E, Arima R, Kishimoto T, Miki T, Kuroda H, Okuyama A. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer. International Journal of Clinical Oncology. 11: 297-302. PMID 16937303 DOI: 10.1007/S10147-006-0562-9 |
0.345 |
|
| 2006 |
Nonomura N, Tokizane T, Nakayama M, Inoue H, Nishimura K, Muramatsu M, Okuyama A. Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients. International Journal of Urology : Official Journal of the Japanese Urological Association. 13: 971-6. PMID 16882065 DOI: 10.1111/J.1442-2042.2006.01450.X |
0.313 |
|
| 2006 |
Yoshioka Y, Konishi K, Oh RJ, Sumida I, Yamazaki H, Nakamura S, Nishimura K, Nonomura N, Okuyama A, Inoue T. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 80: 62-8. PMID 16870289 DOI: 10.1016/J.Radonc.2006.06.011 |
0.332 |
|
| 2006 |
Kaneko Y, Maekawa S, Arakaki R, Okada Y, Terada N, Nishimura K. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer. Hinyokika Kiyo. Acta Urologica Japonica. 52: 259-64. PMID 16686352 |
0.343 |
|
| 2006 |
Takayama H, Nonomura N, Oka D, Shiba M, Arai Y, Nakayama M, Inoue H, Nishimura K, Okuyama A. 1495: Elevated Expression of Tumor-Associated Macrophages is Associated with Poor Prognosis of Human Prostate Cancer The Journal of Urology. 175: 483-483. DOI: 10.1016/S0022-5347(18)33699-1 |
0.408 |
|
| 2005 |
Inoue H, Nishimura K, Oka D, Nakai Y, Shiba M, Tokizane T, Arai Y, Nakayama M, Shimizu K, Takaha N, Nonomura N, Okuyama A. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Letters. 223: 121-8. PMID 15890244 DOI: 10.1016/J.Canlet.2004.09.053 |
0.4 |
|
| 2005 |
Inaba M, Otani Y, Nishimura K, Takaha N, Okuyama A, Koga M, Azuma J, Kawase I, Kasayama S. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment Metabolism-Clinical and Experimental. 54: 55-59. PMID 15562380 DOI: 10.1016/J.Metabol.2004.07.010 |
0.383 |
|
| 2004 |
Tsujimoto Y, Takakuwa T, Takayama H, Nishimura K, Okuyama A, Aozasa K, Nonomura N. In situ shortening of CAG repeat length within the androgen receptor gene in prostatic cancer and its possible precursors. The Prostate. 58: 283-290. PMID 14743468 DOI: 10.1002/Pros.10333 |
0.366 |
|
| 2004 |
Nonomura N, Nishimura K, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A. WS3-3 Genetic alterations in cancer and cancer-related lesions in the human prostate The Japanese Journal of Urology. 95: 241. DOI: 10.5980/Jpnjurol.95.241_2 |
0.378 |
|
| 2002 |
Nonomura N, Nishimura K, Takaha N, Inoue H, Nomoto T, Mizutani Y, Nakao M, Okuyama A, Miki T. Nerve-sparing retroperitoneal lymph node dissection for advanced testicular cancer after chemotherapy. International Journal of Urology. 9: 539-544. PMID 12445231 DOI: 10.1046/J.1442-2042.2002.00520.X |
0.35 |
|
| 2002 |
Tsujimoto Y, Nonomura N, Takayama H, Yomogida K, Nozawa M, Nishimura K, Okuyama A, Nozaki M, Aozasa K. Utility of immunohistochemical detection of prostate-specific Ets for the diagnosis of benign and malignant prostatic epithelial lesions. International Journal of Urology. 9: 167-172. PMID 12010329 DOI: 10.1046/J.1442-2042.2002.00444.X |
0.377 |
|
| 2002 |
Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, Tsujimura A, Kongkanand A, Okuyama A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. International Journal of Cancer. Journal International Du Cancer. 98: 167-72. PMID 11857403 DOI: 10.1002/Ijc.10178 |
0.336 |
|
| 2002 |
Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C. A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. The Journal of Biological Chemistry. 277: 4609-17. PMID 11673464 DOI: 10.1074/Jbc.M108312200 |
0.375 |
|
| 2001 |
Fujita K, Nishimura K, Nonomura N, Hirota S, Okuyama A. Early stage small cell carcinoma of the urinary bladder. International Journal of Urology. 8: 643-644. PMID 11903694 DOI: 10.1046/J.1442-2042.2001.00388.X |
0.355 |
|
| 2001 |
Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. Journal of the National Cancer Institute. 93: 1739-46. PMID 11717335 DOI: 10.1093/Jnci/93.22.1739 |
0.382 |
|
| 2001 |
Ono Y, Nonomura N, Harada Y, Fukui T, Tokizane T, Sato E, Nakayama M, Nishimura K, Takahara S, Okuyama A. Loss of p73 induction in a cisplatin-resistant bladder cancer cell line. Molecular Urology. 5: 25-30. PMID 11689148 DOI: 10.1089/109153601750124267 |
0.302 |
|
| 2001 |
Fukui T, Nonomura N, Tokizane T, Sato E, Ono Y, Harada Y, Nishimura K, Takahara S, Okuyama A. Clinical evaluation of human telomerase catalytic subunit in bladder washings from patients with bladder cancer. Molecular Urology. 5: 19-23. PMID 11689147 DOI: 10.1089/109153601750124249 |
0.319 |
|
| 2001 |
Yoshimura K, Yoshioka T, Miyake O, Nishimura K, Miyoshi S, Takahara S, Okuyama A. Evaluation of the efficacy and safety of laparoscopic nephrectomy International Journal of Urology. 8: 37-41. PMID 11240823 DOI: 10.1046/J.1442-2042.2001.00247.X |
0.305 |
|
| 2000 |
Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, Nishimura K, Takaha N, Takahara S, Okuyama A. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. European Urology. 38: 701-705. PMID 11111187 DOI: 10.1159/000020365 |
0.309 |
|
| 2000 |
Imamura M, Nishiyama H, Ohmori K, Nishimura K. Squamous cell carcinoma of the prostate without evidence of recurrence 5 years after operation. Urologia Internationalis. 65: 122-124. PMID 11025437 DOI: 10.1159/000064853 |
0.416 |
|
| 2000 |
Nonomura N, Nishimura K, Ono Y, Fukui T, Harada Y, Takaha N, Takahara S, Okuyama A. Soluble Fas in serum from patients with renal cell carcinoma. Urology. 55: 151-155. PMID 10654915 DOI: 10.1016/S0090-4295(99)00379-9 |
0.365 |
|
| 1999 |
Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, Ting HJ, Rahman M, Lin HK, Fujimoto N, Hu YC, Mizokami A, Huang KE, Chang C. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine. 11: 195-202. PMID 10709768 DOI: 10.1385/Endo:11:2:195 |
0.364 |
|
| 1999 |
Harada Y, Nonomura N, Kondo M, Nishimura K, Takahara S, Miki T, Okuyama A. Clinical Study of Brain Metastasis of Renal Cell Carcinoma European Urology. 36: 230-235. PMID 10450008 DOI: 10.1159/000068003 |
0.327 |
|
| 1998 |
Miki T, Nonomura N, Takaha N, Nishimura K, Kojima Y, Sawada M, Okuyama A. Antitumor Effect of Irinotecan Hydrochloride (CPT‐11) on Human Renal Tumors Heterotransplanted in Nude Mice International Journal of Urology. 5: 370-373. PMID 9712447 DOI: 10.1111/J.1442-2042.1998.Tb00369.X |
0.313 |
|
| 1998 |
Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C. Retinoblastoma, a Tumor Suppressor, Is a Coactivator for the Androgen Receptor in Human Prostate Cancer DU145 Cells☆ Biochemical and Biophysical Research Communications. 248: 361-367. PMID 9675141 DOI: 10.1006/Bbrc.1998.8974 |
0.374 |
|
| 1998 |
Miki T, Nonomura N, Nozawa M, Harada Y, Nishimura K, Kojima Y, Takahara S, Okuyama A. Angiogenesis Inhibitor Tnp-470 Inhibits Growth And Metastasis Of A Hormone-Independent Rat Prostatic Carcinoma Cell Line The Journal of Urology. 160: 210-213. DOI: 10.1016/S0022-5347(01)63092-1 |
0.382 |
|
| 1996 |
Nonomura N, Miki T, Yokoyama M, Imazu T, Takada T, Takeuchi S, Kanno N, Nishimura K, Kojima Y, Okuyama A. Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochemical and Biophysical Research Communications. 229: 945-951. PMID 8954998 DOI: 10.1006/Bbrc.1996.1906 |
0.341 |
|
| 1993 |
Yoshimura K, Nishimura K, Miyoshi S, Mizutani S, Mise T, Iwasa K. Father-Son Testicular Cancer Urologia Internationalis. 50: 108-110. PMID 8460444 DOI: 10.1159/000282464 |
0.313 |
|
| 1989 |
Okada Y, Kumada K, Habuchi T, Ohnishi H, Nishimura K, Yoshida O. Total Replacement of the Suprarenal Inferior Vena Cava with an Expanded Polytetrafluoroethylene Tube Graft in 2 Patients with Tumor Thrombi from Renal Cell Carcinoma The Journal of Urology. 141: 111-114. PMID 2908931 DOI: 10.1016/S0022-5347(17)40609-4 |
0.352 |
|
| 1988 |
Habuchi T, Nishimura K, Hida S, Yoshida O. Pulmonary nodules simulating metastasis of germ cell tumor after aggressive chemotherapy. Urologia Internationalis. 43: 248-252. PMID 2460985 DOI: 10.1159/000281348 |
0.315 |
|
| 1987 |
Nishimura K, Okada Y, Okada K, Yoshida O, Amitani R, Kubo Y, Ushida S. Spontaneous regression of pulmonary metastasis from renal pelvic cancer. Urologia Internationalis. 42: 461-463. PMID 3329423 DOI: 10.1159/000282017 |
0.355 |
|
| Show low-probability matches. |